A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (LUNG-MAP Sub-study)

Protocol No
SWOG-LUNGMAP-S1900A
Principal Investigator
Smitha Menon
Phase
II
Summary
This study is being done to answer the following question: Can we lower the chance of your lung cancer growing or spreading by using a drug that targets a biomarker present in your tumor? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your lung cancer. The usual approach is defined as care most people get for their lung cancer.
Description
Rucaparib in Patients with Genomic LOH High And/Or Deleterious BRCA1/2 Mutation NSCLC
Participating Institutions
Froedtert Hospital
St. Joseph's Hospital - West Bend
Community Memorial Hospital
Status
OPEN TO ACCRUAL
Share This: